Abstract
A statistical model is essential in determining the appropriate predictive indicators for therapies in many types of cancers. Predictors have been compared favorably to the traditional systems for many cancers. Thus, this study has been proposed as an alternative or a new standard approach. A recent study on the clinical efficacy of Atractylodes lancea (Thunb) DC. (AL) revealed the higher clinical benefits in patients with advanced-stage intrahepatic cholangiocarcinoma (ICC) treated with AL compared with standard supportive care. we investigated the relationships between clinical efficacy and pharmacokinetic parameters of serum bioactivity of AL and its active constituent “atractylodin” and determined therapeutic ranges. Cox proportion hazard model and Receive Operating Characteristic (ROC) were applied to determine the cut-off values of AUC0-inf, Cmax, and Cavg associated with therapeutic outcomes. Number-need to be treated (NNT) and relative risk (RR) was also applied to determine potential predictors. The AUC0-inf of total AL bioactivity of> 96.71 µg*h/ml was identified as a promising predictor of disease prognosis, i.e., progression-free survival (PFS) and disease control rate (DCR). Cmax of total AL bioactivity of>21.42 was identified as a predictor of the prognosis of death. The therapeutic range of total AL bioactivity for PFS and DCR is 14.48-65.8 µg/ml, and for overall survival is 10.97-65.8 µg/ml. The predictors of ICC disease prognosis were established based on the pharmacokinetics of total AL bioactivity. The information could be exploited to improve the clinical efficacy of AL in patients with advanced-stage ICC. These predictors will be validated in a phase 2B clinical study.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
TCTR20210129007
Funding Statement
This work was supported by Thammasat Postdoctoral Fellowship, the Thailand Science Research and Innovation Fundamental Fund. Also, it was received funding from Thammasat University under the project Center of Excellence in Pharmacology, and Molecular Biology of Malaria, and Cholangiocarcinoma (No. 1/2556, dated 12 October 2013), and the National Research Council of Thailand (No. 45/2561, dated 10 September 2018). KN is supported by the National Research Council of Thailand under the Research Team Promotion grant (grant number NRCT 820/2563, dated 12 November 2020). All funders have no roles for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee of Thammasat University (Medicine) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and/or its Supplementary Materials and methods. Any additional data are available from the corresponding author K.N. upon reasonable request.